BioPharma APAC reports that rBIO’s lead biosimilar insulin candidate, R‑biolin, achieved bioequivalence to Novo Nordisk’s Novolin® R in animal studies—an important validation step that clears the path for a 50‑fold manufacturing scale‑up and the first‑in‑human trials planned for later this year.

Bioequivalence confirmed: Pre‑clinical data demonstrate pharmacokinetic and pharmacodynamic parity with Novolin® R.